Adjuvant S-1 Plus Endocrine Therapy for ER+/HER2− Primary Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant S-1 Plus Endocrine Therapy for Oestrogen Receptor-Positive, HER2-Negative, Primary Breast Cancer: A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial
Lancet Oncol 2021 Jan 01;22(1)74-84, M Toi, S Imoto, T Ishida, Y Ito, H Iwata, N Masuda, H Mukai, S Saji, A Shimizu, T Ikeda, H Haga, T Saeki, K Aogi, T Sugie, T Ueno, T Kinoshita, Y Kai, M Kitada, Y Sato, K Jimbo, N Sato, H Ishiguro, M Takada, Y Ohashi, S OhnoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.